Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPED Regimen for Relapsed/Refractory or Advanced NK/T-cell Lymphoma
NCT04405375Phase 2Unknown
- Sponsor
- Beijing Tongren Hospital
- Start
- Mar 2020
- Primary completion
- Apr 2023
- Modality
- Therapeutic Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, pegaspargase, etoposide, dexamethasone in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Beijing Tongren Hospital. Status: unknown.
02
Drugs
gemcitabinepegaspargaseetoposidedexamethasone
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT04405375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04405375.